MARYVILLE, Tenn. – (Sept 17, 2015) – Geneuity and Molecular Pathology Laboratory Network (MPLN) today announced that it is expanding its integrated oncology specialty testing offering to include Next Generation Sequencing assays for solid tumor. The new panels will address Lung, Colon, Melanoma and an unknown primary 8 gene panel with soon to be released Gastrointestinal Stroma, Glioma, Ovarian, Renal and Thyroid solid tumor panels. Geneuity will be making the QIAGEN Human Tumor Actionable Mutations Panel available for clinical trial studies.
Dr. Jamie Platt, Vice President of Genomic Solutions at Geneuity and Molecular Pathology Laboratory Network, Inc., evaluated the illumina TruSight® Tumor 15 and said the panel’s simplicity and ease of use makes it well-suited for translational labs, “The value and appeal of next-generation sequencing is the potential to consolidate traditionally iterative tumor analyses. Our evaluation of the new TruSight Tumor 15, with its streamlined library prep and sequencing workflow, gives us confidence that this application is ideal for deployment. Even our most challenging samples produced results, including those with low nucleic acid inputs, giving us assurance we can analyze our most precious specimens.”
Maryville, Tennessee – (July 15, 2015) – (Business Wire). Geneuity today announced that it is expanding early access to Thermo Fisher Scientific’s targeted, next generation sequencing (NGS) technology and Oncomine Focus Assay for services it plans to offer to its broad pharmaceutical customer base.